Cancer prevention research (Philadelphia, Pa.)
Factors Associated with Low-Dose Tamoxifen Use Among Women with Atypical Hyperplasia, Lobular or Ductal Carcinoma In Situ.
Maya S Deshmukh, Margaret H Kyle, Peter J Zeiger, Vicky Ro, Julia E McGuinness, Alissa Michel, Romi Eli, Rita Kukafka, Katherine D Crew
Published: 202510.1158/1940-6207.CAPR-25-0247
Abstract
In 2019, professional guidelines incorporated low-dose tamoxifen as an option for breast cancer chemoprevention among women with atypical hyperplasia (AH), lobular or ductal carcinoma in situ (LCIS/DCIS). We assessed factors associated with low-dose…
Preview only. Read the full abstract at the source